Metastasis-directed therapy (MDT) in oligometastatic prostate cancer has the potential of delaying the start of androgen deprivation therapy (ADT) and disease progression. We aimed to analyze the efficacy of PSMA-PET/CT in detecting oligometastatic disease (OMD), to look for predictive factors of OMD, and to evaluate the impact of PSMA-PET/CT findings on clinical management. We retrospectively analyzed a homogeneous population of 196 hormone-sensitive prostate cancer patients (HSPC), considered potential candidates for MDT, with a PSMA-PET/CT performed at biochemical recurrence (BCR) after radical prostatectomy (RP). Multivariable logistic regression analysis was performed based on several clinico-pathological factors. Changes in clinical management before and after PSMA-PET/CT were analyzed. The OMD detection rate was 44% for a total positivity rate of 60%. PSMA-PET/CT positivity was independently related to PSA (OR (95% CI), ) (1.7 (1.3-2.3), < 0.0001) and PSAdt (0.4 (0.2-0.8), = 0.013), and OMD detection was independently related to PSA (1.6 (1.2-2.2), = 0.001) and no previous salvage therapy (0.3 (0.1-0.9), = 0.038). A treatment change was observed in 58% of patients, mostly to perform MDT after OMD detection (60% of changes). This study showed that PSMA-PET/CT is an excellent imaging technique to detect OMD early in HSPC patients with BCR after RP, changing therapeutic management mostly into MDT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508549PMC
http://dx.doi.org/10.3390/cancers13194982DOI Listing

Publication Analysis

Top Keywords

prostate cancer
12
omd detection
12
oligometastatic disease
8
hormone-sensitive prostate
8
cancer patients
8
patients hspc
8
biochemical recurrence
8
radical prostatectomy
8
predictive factors
8
clinical management
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!